About 21st.BIO
21st.BIO is a company based in Virum (Denmark) founded in 2020. 21st.BIO has raised $152.85 million across 3 funding rounds from investors including Novo Holdings. The company has 38 employees as of November 30, 2024. 21st.BIO offers products and services including Dairy Proteins, Protein Sweeteners, Collagen, Biomaterials, and Agriculture Solutions.
- Headquarter Virum, Denmark
- Employees 38 as on 30 Nov, 2024
- Stage Minicorn
-
Sectors
Consumer
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name 21St.Bio A/S
-
Annual Revenue
Not available
-
Net Profit
-$5.19 M (USD)-68as on Dec 31, 2022
-
EBITDA
-$7.68 M (USD)-149as on Dec 31, 2022
-
Total Equity Funding
$152.85 M (USD)
in 3 rounds
-
Latest Funding Round
$21.76 M (USD), Series C
Jun 01, 2023
- Investors
-
Employee Count
38
as on Nov 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of 21st.BIO
21st.BIO offers a comprehensive portfolio of products and services, including Dairy Proteins, Protein Sweeteners, Collagen, Biomaterials, and Agriculture Solutions.
Development and scaling of proteins for dairy applications
Optimized sweeteners for food and industrial use
Production of collagen for biomaterials and health sectors
Advanced materials for various industrial applications
Strain development for agricultural biomining processes
Techniques for resource extraction in mining industries
People of 21st.BIO
Unlock access to complete
Funding Insights of 21st.BIO
21st.BIO has successfully raised a total of $152.85M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $21.76 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in 21st.BIO
21st.BIO has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked |
Investor details for 21st.BIO
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by 21st.BIO
Investment portfolio details for 21st.BIO
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - 21st.BIO
Detailed financials for 21st.BIO
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
21St.Bio Comparisons
Peer comparison for 21st.BIO
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of 21st.BIO
Detailed competitors of 21st.BIO
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on 21St.Bio
Complete news archive for 21st.BIO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about 21st.BIO
21st.BIO was founded in 2020 and raised its 1st funding round 1 year after it was founded.
21st.BIO is headquartered in Virum, Denmark.
21st.BIO is a funded company, having raised a total of $152.85M across 3 funding rounds to date.
As of Nov 30, 2024, the latest employee count at 21st.BIO is 38.
21st.BIO was established in 2020 and is based in Virum, Denmark. Market research tailored to the biopharma industry is conducted, with a focus on data analysis and sector insights. Services encompass competitive intelligence, trend forecasting, and strategic advisory support. Operations are directed toward assisting pharmaceutical and biotechnology firms with evidence-based decision-making across global markets.
21st.BIO offers Dairy Proteins, Protein Sweeteners, Collagen, Biomaterials, and 2 more products and services.
21st.BIO has 1 investor. Key investors include Novo Holdings.
The valuation of 21st.BIO is $91.79M as of Jun 2023.